Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr598 Inhibitors

Olr598 inhibitors represent a specialized class of chemical compounds designed to interact with and inhibit the activity of the Olr598 receptor. The Olr598 receptor, part of the larger olfactory receptor family, is a G-protein coupled receptor (GPCR) found in various tissues. These inhibitors typically possess high specificity and affinity for the Olr598 receptor, allowing for precise modulation of its activity. Structurally, Olr598 inhibitors often feature unique motifs and functional groups that enable them to bind effectively to the receptor's active site, blocking its normal function. This binding can alter the receptor's conformational state, preventing the usual downstream signaling pathways associated with Olr598 activation.

Chemically, Olr598 inhibitors may be categorized into several subtypes based on their core structures and binding mechanisms. These compounds can include small organic molecules, peptides, and even modified nucleotides, each designed to achieve optimal interaction with the Olr598 receptor. Researchers synthesize these inhibitors through a variety of methods, including traditional organic synthesis, combinatorial chemistry, and high-throughput screening techniques. Characterization of these inhibitors often involves advanced spectroscopic and chromatographic methods, ensuring that their purity and structural integrity meet rigorous standards. Additionally, computational modeling and molecular docking studies are frequently employed to predict and optimize the binding interactions between Olr598 inhibitors and the receptor, providing valuable insights into their potential efficacy and guiding further refinement in the design of new inhibitors.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual inhibitor of EGFR and HER2, potentially affecting proteins in associated signaling pathways.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple kinases, potentially affecting proteins in cell signaling and growth pathways.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted tyrosine kinase inhibitor, potentially influencing proteins involved in angiogenesis and tumor growth.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGF receptors, potentially affecting proteins involved in angiogenesis and tumor growth.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially affecting proteins in these pathways.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Another EGFR tyrosine kinase inhibitor, potentially affecting proteins in the EGFR signaling pathway.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

Inhibits BCR-ABL and c-KIT tyrosine kinases, potentially affecting proteins in associated signaling pathways.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Inhibits Bruton's tyrosine kinase, potentially affecting proteins in B-cell receptor signaling.